Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,383 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: A PROTEIN level Clear all
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Glutathione vs. Curcumin Clinical Trial

NCT02848417
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Curcumin, Glutathione, Placebo
Drug · Other
Lead sponsor
South Florida Veterans Affairs Foundation for Research and Education
Federal
Eligibility
35 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 15, 2026, 6:23 PM EDT
Completed No phase listed Observational

Improving White Matter Integrity With Thyroid Hormone

NCT04098991
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 15, 2026, 6:23 PM EDT
Not listed No phase listed Observational

Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

NCT05439174
View directory record Official record
Conditions
End-stage Renal Disease, Malnutrition; Protein
Interventions
Intradialytic Parenteral Nutrition
Other
Lead sponsor
Patient Care America
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 15, 2026, 6:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 6:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans

NCT04755062
View directory record Official record
Conditions
Obesity, Blood Glucose, High
Interventions
Micronutrient-dense plant-rich Intervention
Behavioral
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 15, 2026, 6:23 PM EDT
Recruiting Phase 3 Interventional

Ketogenic Diet for New-Onset Absence Epilepsy

NCT04274179
View directory record Official record
Conditions
Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence
Interventions
Modified Atkins Diet, Absence epilepsy medications
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 15, 2026, 6:23 PM EDT
Completed Phase 2 Interventional

A Study in People With Abnormal Fat Levels in the Blood

NCT00116519
View directory record Official record
Conditions
Dyslipidemia
Interventions
PPAR alpha, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
54
States / cities
Hoover, Alabama • Fayetteville, Arkansas • San Diego, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 15, 2026, 6:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

NCT00398086
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine, Albumin-bound paclitaxel
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 15, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps

NCT03280537
View directory record Official record
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Tucson, Arizona • Rancho Cordova, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 15, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

NCT01603212
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, IL-2, Interferon Alpha-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 15, 2026, 6:23 PM EDT
Terminated Phase 2 Interventional Results available

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

NCT01518153
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 15, 2026, 6:23 PM EDT
Withdrawn Not applicable Interventional

Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes

NCT04088981
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dietary intervention
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 15, 2026, 6:23 PM EDT
Terminated Phase 1 Interventional

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

NCT04659122
View directory record Official record
Conditions
COVID-19, Undefined
Interventions
AT-100
Biological
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 15, 2026, 6:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

NCT05255601
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions
Relatlimab, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 30 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 15, 2026, 6:23 PM EDT
Withdrawn Not applicable Interventional

Short-Term Endogenous Hydrogen Sulfide Upregulation For Vein Graft Disease

NCT05457881
View directory record Official record
Conditions
Vascular Diseases, Surgery
Interventions
Scandi-Shake
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 15, 2026, 6:23 PM EDT
Completed Not applicable Interventional

Asthma L-Citrulline Pilot Study

NCT02943161
View directory record Official record
Conditions
Asthma
Interventions
L-Citrulline
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Aurora, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 15, 2026, 6:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Influence of Aerobic Training and Weight Loss on Skeletal Muscle Inflammatory Markers and Muscle Protein Balance in Older Adults

NCT03743675
View directory record Official record
Conditions
Overweight and Obesity, Inflammation; Muscle, Sedentary Lifestyle
Interventions
Diet-Induced Weight Loss, Aerobic Exercise Training
Behavioral
Lead sponsor
Miami University
Other
Eligibility
58 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 15, 2026, 6:23 PM EDT
Terminated Phase 2 Interventional Results available

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

NCT03823131
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
ImmunoPulse, Epacadostat, Pembrolizumab, CORVax, Tavokinogene telseplasmid
Device · Drug · Biological
Lead sponsor
Chase Heaton, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 15, 2026, 6:23 PM EDT
Completed Not applicable Interventional

Impact of Weight Loss on Physical Function

NCT02079051
View directory record Official record
Conditions
Obesity
Interventions
Moderate intensity weight loss, High intensity medical weight loss
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 15, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

NCT01147666
View directory record Official record
Conditions
End Stage Renal Disease, Anemia
Interventions
Roxadustat, Epoetin Alfa, Placebo
Drug · Other
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 15, 2026, 6:23 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

NCT06825858
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
KH658
Drug
Lead sponsor
Chengdu Origen Biotechnology Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Lemont, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 15, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

NCT01409135
View directory record Official record
Conditions
Tumors, Medical Oncology, Neoplasms
Interventions
AGS-22M6E, ASG-22CE
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 15, 2026, 6:23 PM EDT
Active, not recruiting Phase 1 Interventional

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

NCT01061515
View directory record Official record
Conditions
Carcinoma
Interventions
Intraperitoneal Oxaliplatin, Bevacizumab, Capecitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 6:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Growth Hormone and Bone in Obesity

NCT01724489
View directory record Official record
Conditions
Obesity, Osteopenia
Interventions
Growth hormone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 15, 2026, 6:23 PM EDT